BRPI0408006A - uso de ácidos graxos Èmega -3 no tratamento de pacientes diabéticos - Google Patents
uso de ácidos graxos Èmega -3 no tratamento de pacientes diabéticosInfo
- Publication number
- BRPI0408006A BRPI0408006A BRPI0408006-8A BRPI0408006A BRPI0408006A BR PI0408006 A BRPI0408006 A BR PI0408006A BR PI0408006 A BRPI0408006 A BR PI0408006A BR PI0408006 A BRPI0408006 A BR PI0408006A
- Authority
- BR
- Brazil
- Prior art keywords
- fatty acids
- omega
- treatment
- diabetic patients
- ethyl ester
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Diabetes (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Emergency Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
"USO DE áCIDOS GRAXOS ÈMEGA -3 NO TRATAMENTO DE PACIENTES DIABéTICOS". A presente invenção refere-se ao uso de ácidos graxos essenciais com um alto teor de éster de etila de ácido eicosapentenóico (EPA) ou de éster de etila de ácido docosahexaenóico (DHA) útil para evitar eventos cardiovasculares em pacientes com diabetes melito.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP03004792 | 2003-03-05 | ||
PCT/EP2004/050238 WO2004078166A2 (en) | 2003-03-05 | 2004-03-02 | Use of omega-3-fatty acids in the treatment of diabetic patients |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0408006A true BRPI0408006A (pt) | 2006-02-14 |
Family
ID=32946844
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0408006-8A BRPI0408006A (pt) | 2003-03-05 | 2004-03-02 | uso de ácidos graxos Èmega -3 no tratamento de pacientes diabéticos |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP1603551A2 (pt) |
JP (1) | JP2006519244A (pt) |
CN (1) | CN1756545A (pt) |
AU (1) | AU2004216856A1 (pt) |
BR (1) | BRPI0408006A (pt) |
CA (1) | CA2515328A1 (pt) |
MX (1) | MXPA05009432A (pt) |
WO (1) | WO2004078166A2 (pt) |
Families Citing this family (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9901809D0 (en) | 1999-01-27 | 1999-03-17 | Scarista Limited | Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes |
WO2006073147A1 (ja) | 2005-01-04 | 2006-07-13 | Mochida Pharmaceutical Co., Ltd. | 脂肪毒性の改善剤 |
CN101213281B (zh) * | 2005-05-04 | 2013-03-13 | 普罗诺瓦生物医药挪威公司 | 新的dha衍生物及其作为药物的用途 |
US20090203778A1 (en) * | 2005-05-04 | 2009-08-13 | Morten Bryhn | Fatty acid analogues, i.e. including dha derivatives for uses as a medicament |
KR101255650B1 (ko) * | 2005-05-04 | 2013-04-16 | 프로노바 바이오파마 너지 에이에스 | 새로운 dha 유도체 및 약제로서의 용도 |
JP5134916B2 (ja) * | 2005-07-08 | 2013-01-30 | 持田製薬株式会社 | 心血管イベント発症予防用組成物 |
EP1790339B1 (en) * | 2005-07-08 | 2014-06-04 | Mochida Pharmaceutical Co., Ltd. | Composition for prevention of occurrence of cardiovascular event |
RU2507193C2 (ru) * | 2006-11-01 | 2014-02-20 | Пронова Биофарма Норге А/С | Альфа-замещенные омега-3 липиды, которые являются активаторами или модуляторами рецептора, активируемого пролифераторами пероксисом (ppar) |
BRPI0717883A2 (pt) * | 2006-11-01 | 2013-10-29 | Pronova Biopharma Norge As | Compostos lipídicos, composição contendo os mesmos e uso dos referidos compostos |
CN101535238A (zh) * | 2006-11-01 | 2009-09-16 | 普罗诺瓦生物医药挪威公司 | 作为过氧化物酶体增生物激活受体(PPAR)的活化剂或调节剂的α-取代的ω-3脂质 |
JP2010509204A (ja) * | 2006-11-03 | 2010-03-25 | プロノヴァ バイオファーマ ノルゲ アーエス | 脂肪酸アルコール |
JPWO2010018856A1 (ja) * | 2008-08-13 | 2012-01-26 | 持田製薬株式会社 | カンナビノイド受容体関連疾患の予防/改善または治療剤 |
US20110236476A1 (en) | 2008-09-02 | 2011-09-29 | Amarin Corporation Plc. | Pharmaceutical composition comprising eicosapentaenoic acid and nicotinic acid and methods of using same |
KR20140007973A (ko) | 2009-02-10 | 2014-01-20 | 아마린 파마, 인크. | 고중성지방혈증 치료 방법 |
NZ627238A (en) | 2009-04-29 | 2016-02-26 | Amarin Pharmaceuticals Ie Ltd | Stable pharmaceutical composition comprising ethyl eicosapentaenoate |
NZ624963A (en) | 2009-04-29 | 2016-07-29 | Amarin Pharmaceuticals Ie Ltd | Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same |
MY172372A (en) | 2009-06-15 | 2019-11-21 | Amarin Pharmaceuticals Ie Ltd | Compositions and methods for lowering triglycerides |
FR2949063B1 (fr) * | 2009-08-11 | 2011-09-30 | Pf Medicament | Composition pharmaceutique comprenant un ester de dha destinee a etre administree par voie parenterale |
WO2011038122A1 (en) | 2009-09-23 | 2011-03-31 | Amarin Corporation Plc | Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same |
CN104814950A (zh) * | 2010-11-09 | 2015-08-05 | 持田制药株式会社 | 血糖值上升抑制剂在制造经口摄取用食品中的应用 |
US11712429B2 (en) | 2010-11-29 | 2023-08-01 | Amarin Pharmaceuticals Ireland Limited | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
NZ744990A (en) | 2010-11-29 | 2019-10-25 | Amarin Pharmaceuticals Ie Ltd | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
US11291643B2 (en) | 2011-11-07 | 2022-04-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating hypertriglyceridemia |
US20130131170A1 (en) | 2011-11-07 | 2013-05-23 | Amarin Pharmaceuticals Ireland Limited | Methods of treating hypertriglyceridemia |
EP2800469B1 (en) | 2012-01-06 | 2021-08-25 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering levels of high-sensitivity (hs-crp) in a subject |
EP2866801A4 (en) | 2012-06-29 | 2016-02-10 | Amarin Pharmaceuticals Ie Ltd | METHODS OF REDUCING THE RISK OF A CARDIOVASCULAR EVENT IN A SUBJECT SUBJECTED TO STATIN TREATMENT |
WO2014074552A2 (en) | 2012-11-06 | 2014-05-15 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy |
US9814733B2 (en) | 2012-12-31 | 2017-11-14 | A,arin Pharmaceuticals Ireland Limited | Compositions comprising EPA and obeticholic acid and methods of use thereof |
US20140187633A1 (en) | 2012-12-31 | 2014-07-03 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis |
US9452151B2 (en) | 2013-02-06 | 2016-09-27 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing apolipoprotein C-III |
US9624492B2 (en) | 2013-02-13 | 2017-04-18 | Amarin Pharmaceuticals Ireland Limited | Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof |
US9662307B2 (en) | 2013-02-19 | 2017-05-30 | The Regents Of The University Of Colorado | Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof |
US9283201B2 (en) | 2013-03-14 | 2016-03-15 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for treating or preventing obesity in a subject in need thereof |
US20140271841A1 (en) | 2013-03-15 | 2014-09-18 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin |
US10966968B2 (en) | 2013-06-06 | 2021-04-06 | Amarin Pharmaceuticals Ireland Limited | Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof |
US20150065572A1 (en) | 2013-09-04 | 2015-03-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing prostate cancer |
US9585859B2 (en) | 2013-10-10 | 2017-03-07 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy |
US10561631B2 (en) | 2014-06-11 | 2020-02-18 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing RLP-C |
WO2015195662A1 (en) | 2014-06-16 | 2015-12-23 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense ldl or membrane polyunsaturated fatty acids |
US10406130B2 (en) | 2016-03-15 | 2019-09-10 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids |
WO2018213663A1 (en) | 2017-05-19 | 2018-11-22 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides in a subject having reduced kidney function |
US11058661B2 (en) | 2018-03-02 | 2021-07-13 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L |
KR102296068B1 (ko) | 2018-09-24 | 2021-09-02 | 애머린 파마슈티칼스 아일랜드 리미티드 | 대상체에서 심혈관 사건의 위험도를 감소시키는 방법 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS60248610A (ja) * | 1984-05-23 | 1985-12-09 | Nitsusui Seiyaku Kk | 糖尿病合併症の予防および治療剤 |
GB2218904A (en) * | 1988-05-27 | 1989-11-29 | Renafield Limited | Pharmaceutical composition based on high-concentration esters of docosahexaenoic acid |
GB2223943A (en) * | 1988-10-21 | 1990-04-25 | Tillotts Pharma Ag | Oral disage forms of omega-3 polyunsaturated acids |
-
2004
- 2004-03-02 JP JP2006505440A patent/JP2006519244A/ja active Pending
- 2004-03-02 WO PCT/EP2004/050238 patent/WO2004078166A2/en not_active Application Discontinuation
- 2004-03-02 AU AU2004216856A patent/AU2004216856A1/en not_active Abandoned
- 2004-03-02 CA CA002515328A patent/CA2515328A1/en not_active Abandoned
- 2004-03-02 MX MXPA05009432A patent/MXPA05009432A/es unknown
- 2004-03-02 BR BRPI0408006-8A patent/BRPI0408006A/pt not_active Application Discontinuation
- 2004-03-02 CN CNA2004800055600A patent/CN1756545A/zh active Pending
- 2004-03-02 EP EP04737282A patent/EP1603551A2/en not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
WO2004078166A3 (en) | 2004-10-28 |
MXPA05009432A (es) | 2005-11-23 |
JP2006519244A (ja) | 2006-08-24 |
EP1603551A2 (en) | 2005-12-14 |
WO2004078166A2 (en) | 2004-09-16 |
AU2004216856A1 (en) | 2004-09-16 |
CA2515328A1 (en) | 2004-09-16 |
CN1756545A (zh) | 2006-04-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0408006A (pt) | uso de ácidos graxos Èmega -3 no tratamento de pacientes diabéticos | |
WO2009091538A3 (en) | Pharmaceutical composition comprising epa and dha for treating hypertriglyceridemia and hypercholesterolemia | |
PT1310249E (pt) | Utilizacao de acidos gordos poli-insaturados para prevencao primaria de eventos cardiovasculares graves | |
BRPI0418921A (pt) | uso de ácidos graxos poliinsaturados, composição nutricional, e, uso de uma composição | |
WO2008018043A3 (en) | Methods of improving bone health and muscle health | |
DK1152755T3 (da) | Essentielle fedtsyrer til forebyggelse af cardiovaskulære tilfælde | |
WO2005089744A3 (en) | Use of docosatrienes, resolvins and their stable analogs in the treatment of airway diseases and asthma | |
MY162133A (en) | Nutritional supplement containing long-chain polyunsaturated fatty acids | |
KR940018090A (ko) | 트리글리세라이드 | |
NO975299L (no) | Nµringsstoff til behandling av metabolsk syndrom | |
BR0209749A (pt) | Coenzima q e epa ou outro ácido graxo essencial | |
BRPI0512528A (pt) | uso de ácidos graxos poliinsaturados, composição nutricional, e, uso de uma composição | |
DE60330154D1 (de) | Resolvine: biotemplate zur durchführung therapeutischer anwendungen | |
WO2007017240A3 (en) | Composition of n-3 fatty acids having high concentration of epa and/or dha and containing n-6 fatty acids | |
BR0112073A (pt) | Combinações terapêuticas de ácidos graxos | |
DE602005021668D1 (de) | Pharmazeutische formulierung mit statinmikrokapseln in alkylestern mehrfach ungesättigter fettsäuren | |
MXPA05003346A (es) | Control glicemico mejorado para prediabetes y/o diabetes tipo ii utilizando acido docosahexaenoico. | |
WO2008036353A3 (en) | Omega-3 diglyceride emulsions | |
HUP0303019A2 (hu) | Esszenciális N-3 zsírsavakat tartalmazó gyógyszerkészítmények alkalmazása a szívgyengeség és szívelégtelenség terápiájában | |
EP1765324A4 (en) | COMPOSITIONS BASED ON STABLE BIOACTIVE METABOLITES OF DOCOSAHEXANOIC (DHA) AND EICOSAPENTANOIC ACIDS (EPA) | |
CO6150156A2 (es) | Esteres de dha y su utilizacion en el tratamiento y la prevencion de enfermedades cardiovasculares | |
WO2003072111A3 (en) | Omega-3 fatty acids or omega-3 phosphatidylcholine in the treatment of depression | |
Tsukui et al. | Enhancement of hepatic docosahexaenoic acid and arachidonic acid contents in C57BL/6J mice by dietary fucoxanthin | |
Hiratsuka et al. | Effect of dietary docosahexaenoic acid connecting phospholipids on the lipid peroxidation of the brain in mice | |
DE60101859D1 (de) | Pinolensäure gegen Diabetes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
B11Y | Definitive dismissal acc. article 33 of ipl - extension of time limit for request of examination expired |